文献速递癫痫神经重症与神经感染

Brexanolone作为超级难治性癫痫持续状态的辅助治疗

Brexanolone as adjunctive therapy in super-refractory status epilepticus.
PubMed 文献 · Ann Neurol · 2017-09-11

这项多中心1/2期开放标签研究评估了Brexanolone(神经活性类固醇allopregnanolone的水溶性制剂)在超级难治性癫痫持续状态(SRSE)患者中的安全性和耐受性,次要目标包括药代动力学评估及停用麻醉性三线药物(TLA)期间和之后Brexanolone反应的开放标签评价。

要点

  • Brexanolone在异质性病因的SRSE患者中表现出耐受性。
  • 77%的撤药尝试者在Brexanolone减量前成功撤除TLA。
  • 73%在开始输注5天内撤除TLA且24小时内未重新使用麻醉剂。

核心结论

  • 在有限样本的开放标签队列中,Brexanolone在异质性病因的SRSE患者中表现出耐受性,并与高比例的成功TLA撤药相关。
  • 结果提示Brexanolone可能开发为需要药理昏迷控制发作的SRSE的辅助治疗。

研究设计与样本

  • 多中心、1/2期、开放标签研究,评估Brexanolone在SRSE患者中的安全性和耐受性。
  • 患者接受1小时Brexanolone负荷输注,随后维持输注;输注48小时后在维持期间撤除TLA,4天后逐渐减量。

主要发现

  • 未发生由安全审查委员会确定的归因于研究药物的严重不良事件(SAE)。

临床怎么用

  • 对于需要麻醉性三线药物控制发作的SRSE患者,Brexanolone可作为辅助治疗选择,有助于撤除TLA。
  • 使用期间需监测SAE,但本研究未发现归因于研究药物的SAE。

局限性

  • 研究为1/2期,主要评估安全性和耐受性,疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Super-refractory status epilepticus (SRSE) is a life-threatening form of status epilepticus that continues or recurs despite 24 hours or more of anesthetic treatment. We conducted a multicenter, phase 1/2 study in SRSE patients to evaluate the safety and tolerability of brexanolone (USAN; formerly SAGE-547 Injection), a proprietary, aqueous formulation of the neuroactive steroid, allopregnanolone. Secondary objectives included pharmacokinetic assessment and open-label evaluation of brexanolone response during and after anesthetic third-line agent (TLA) weaning. METHODS: Patients receiving TLAs for SRSE control were eligible for open-label, 1-hour brexanolone loading infusions, followed by maintenance infusion. After 48 hours of brexanolone infusion, TLAs were weaned during brexanolone maintenance. After 4 days, the brexanolone dose was tapered. Safety and functional status were assessed over 3 weeks of follow-up. RESULTS: Twenty-five patients received open-label study drug. No serious adverse events (SAEs) were attributable to study drug, as determined by the Safety Review Committee. Sixteen patients (64%) experienced ≥1 SAE. Six patient deaths occurred, all deemed related to underlying medical conditions. Twenty-two patients underwent ≥1 TLA wean attempt. Seventeen (77%) met the response endpoint of weaning successfully off TLAs before tapering brexanolone. Sixteen (73%) were successfully weaned off TLAs within 5 days of initiating brexanolone infusion without anesthetic agent reinstatement in the following 24 hours. INTERPRETATION: In an open-label cohort of limited size, brexanolone demonstrated tolerability among SRSE patients of heterogeneous etiologies and was associated with a high rate of successful TLA weaning. The results suggest the possible development of brexanolone as an adjunctive therapy for SRSE requiring pharmacological coma for seizure control. Ann Neurol 2017;82:342-352.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Rosenthal ES, Claassen J, Wainwright MS, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017. PMID: 28779545. doi:10.1002/ana.25008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。